as a prerequisite for treatment modality with targeted therapy, apart from the best supportive care alone. 1, 4 Therefore, accurate detection of KRAS mutations is critical to clinical decision-making.
Current detection technologies for KRAS mutations mainly include
Sanger sequencing, pyrosequencing, amplification refractory mutation system (ARMS), 5 high-resolution melting real-time PCR (PCR-HRM), 6 Beads, Emulsion, Amplification, and Magnetics (BEAMing), 7 digital PCR (dPCR), 8 and next-generation sequencing (NGS). 9 The existing quality control materials can be broadly divided into two categories: (i) samples obtained from tumor patients, including histological samples and specific cell lines and (ii) synthetic samples, such as plasmids. [10] [11] [12] However, the existing quality control materials have drawbacks and do not meet the needs of all the detection methods, particularly NGS.
Histological samples of patients are available in limited amounts and offer poor reproducibility because of tumor heterogeneity. Although cell lines with specific aberrations can be obtained in unlimited amounts, they do not reflect the complex composition of tumor tissues. 11 Even though plasmids are easy to obtain and widely used, it does not fully reflect the biological characteristics and the detection process of clinical samples due to inherent characteristics, such as the lack of a nucleic acid extraction process and background genomic
DNA.
The ideal quality control material for NGS should provide both the tumor mutation gene and the matched background genomic DNA to better distinguish between single nucleotide polymorphisms (SNPs) or germline polymorphisms and somatic mutations. [13] [14] [15] However, both clinical samples and specific cell lines contain SNPs from the individual itself, which are easily confused with tumor mutations. As an essential part of the standardization of clinical laboratory testing, the detection of the KRAS mutation urgently requires a biomimetic material that can be applied to all detection techniques. The clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing technology may offer the means to meet this requirement and provide uniform genetic background information.
HEK293T cells before editing can be used as the genomic background for NGS filtration of SNPs.
In this study, using the CRISPR/Cas9 technology, we aimed to develop a KRAS G12V cell line that could serve as a quality control material that meets all requirements. This is the first attempt at precise genetic editing by CRISPR/Cas9 to generate quality control material.
With this new perspective, the construct may be used as a control or standard in the quality control of routine clinical laboratory tests and diagnosis.
| METHODS AND MATERIALS

| Plasmid construction, primers, and templates design
The pSpCas9(BB)-2A-GFP plasmid (PX458; plasmid #48138) expressing Cas9 endonuclease (Addgene, Cambridge, MA) was linked with a single-guide RNA (sgRNA) designed specifically for the KRAS gene. 16 The KRAS target sequence was obtained from COSMIC 
| Validation of mixed clonal cells
The Eppendorf BioPhotometer was used to quantify DNA concentration. The cleavage efficiencies of sgRNAs were evaluated by the T7EI assay using T7 Endonuclease I (New England BioLabs Inc., Ipswich, MA). 16 The PCR system contained 25 μL PrimeSTAR Max DNA Polymerase (Takara Bio Inc., Shiga, Japan), 1.5 μL T7EI 
| Detection of the mutation using the QuantStudio 3D Digital PCR System
The QuantStudio 3D dPCR System (Thermo Fisher Scientific Inc.)
is an accurate mutation allele fraction (MAF) detection method and was used to validate the generated cell line. Probes specific for G12V
were used for the current analysis; the corresponding assay was 
| Detection of the mutation using NGS
The sequencing library was prepared from 10 ng DNA using the Ion 
| RESULTS
| Generation of KRAS G12V cells using the CRISPR/Cas9 system
The CRISPR/Cas9 system was used to edit the genome of HEK293T cells to generate KRAS mutation hotspots. HDR templates of the three most common mutation types, KRAS G12D/G12V/G13D, were added to the transfection system. To obtain the best possible transfection efficiency, 500 ng and 1 μL were taken as the optimum amounts of the PX458-sgRNA recombinant plasmid and the HDR template (10 μ mol L −1 ), respectively. The transfection efficiency of the recombinant plasmid was about 70%. The T7EI electrophoresis results showed that the cleavage efficiency of sgRNA2 was higher than that of sgRNA1 ( Figure 2 ). Next, ARMS PCR was used to verify that the CRISPR/Cas9-edited cells specifically contained the KRAS G12V mutation ( Figure 3A ). We performed flow cytometry and sorted single cells with a high GFP fluorescence signal to isolate positive monoclonal cells.
| Detection of the mutation using ARMS PCR, Sanger sequencing, QuantStudio 3D Digital PCR System, and NGS
The ARMS PCR and Sanger sequencing results are shown in Figure 3 .
We directly sequenced the PCR products of DNA isolated from the cells. The positive cells were identified with the specific mutation c.35G>T using Sanger sequencing. From the results of the sequence peaks, we observed the presence of wild-type genes at the mutation site ( Figure 3D ). We then linked the PCR products with the pMD18-T vector (Takara Bio Inc.) and sequenced the ssDNA ( Figure 3E ). Except for mutant T and wild-type G, the sequencing products did not contain any other unrelated genes. We screened out only positive monoclonal cells with the G12V mutation. Next, ARMS PCR was used to validate the mutation. The amplification curves of the G12V-positive edited cell lines and the SW480 cell line are shown in Figure 3B . There were no significant differences between the results of the positive cell lines and the SW480 cell line (P > .05, Figure 3C ). After cell passage, there were no statistical differences between the first and fifth generations of the monoclonal cell lines (P > .05, Figure 3C ). Therefore, our novel cell lines were stable through passaging.
| Detection of the mutation using the QuantStudio 3D Digital PCR System and NGS
To further validate the feasibility of the quality control material, we generated and calculated the MAFs of the genomic DNA from the cells; we performed dPCR with the QuantStudio 3D dPCR System and NGS using the Ion PGM platform. We observed that all three cell lines contained the G12V mutation and the MAFs of G12V-1, G12V-2, and G12V-3 were 52.01%, 82.06%, and 17.29%, respectively (Figure 4) . Results from targeted sequencing revealed only the presence of the KRAS G12V mutation in the three positive cell lines as well as in SW480. The MAFs in the edited cell lines derived from NGS were in agreement with the dPCR results. The SW480 and HEK293T cell lines were used as the positive and negative control, respectively, in all the methods. Figure 5 shows the specific mutation present in the three positive cell lines.
| DISCUSSION
Presenting a more aggressive phenotype among the most common KRAS mutations, G12V is associated with worse cancer progression and poorer clinical outcome compared with CRC with wildtype KRAS. [17] [18] [19] [20] The accurate detection of the mutation in clinical Owing to the demand for large amounts of quality control material, it becomes impractical to provide the same material to all laboratories, especially with the use of surgical pathological material. 21 As the first successful attempt at precise gene editing to produce universal quality control material using the CRISPR/Cas9 system, our study shows that this idea is feasible and promising. With features of easy access and full simulation of clinical samples, the generated Primarily, this quality control material can be used for various detection methods. Our results show that the genome of the results for edited KRAS G12V cell line and the SW480 cell line were 100% consistent for all methods. Moreover, the cell line generated from HEK293T cells can provide specific information about SNPs and germline polymorphisms that cannot be found in public databases [13] [14] [15] and is hence more suitable for NGS than other material.
Additionally, compared to synthetic or spike-in samples, the ed- In conclusion, our work introduces a novel and universal cell line with the KRAS G12V mutation, produced using the CRISPR/ Cas9 system, that can help make the detection process amenable to monitoring and has the potential to meet the current requirements 
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